ABMT (Advanced BioMedical Technologies) Debt-to-Asset : 18.50 (As of Jul. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced BioMedical Technologies Debt-to-Asset?

Advanced BioMedical Technologies ABMT Debt-to-Asset is 18.50 as of Jul. 2022.

Advanced BioMedical Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2022 was $7.09 Mil. Advanced BioMedical Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2022 was $0.00 Mil. Advanced BioMedical Technologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jul. 2022 was $0.38 Mil. Advanced BioMedical Technologies's debt to asset for the quarter that ended in Jul. 2022 was 18.50.

Advanced BioMedical Technologies  (OTCPK:ABMT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Advanced BioMedical Technologies Debt-to-Asset Related Terms

Advanced BioMedical Technologies Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Advanced BioMedical Technologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced BioMedical Technologies Debt-to-Asset Chart

Advanced BioMedical Technologies Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.35 27.56 12.64 15.36 17.21

Advanced BioMedical Technologies Quarterly Data
Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.92 15.36 19.10 17.93 18.50

ABMT vs VYCO, ADMT, THMO: Debt-to-Asset Comparison

For the Medical Devices subindustry, Advanced BioMedical Technologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced BioMedical Technologies Debt-to-Asset vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Advanced BioMedical Technologies's Debt-to-Asset falls into.


Advanced BioMedical Technologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Advanced BioMedical Technologies's Debt-to-Asset for the fiscal year that ended in Oct. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.811142 + 0) / 0.395704
=17.21

Advanced BioMedical Technologies's Debt-to-Asset for the quarter that ended in Jul. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(7.094886 + 0) / 0.383486
=18.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 18.50 mean?
Advanced BioMedical Technologies (ABMT) has a Debt-to-Asset of 18.50 as of Jul. 2022. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Advanced BioMedical Technologies and its competitors.
Is Advanced BioMedical Technologies' Debt-to-Asset too high?
Advanced BioMedical Technologies' current Debt-to-Asset is 18.50.
How does Advanced BioMedical Technologies' Debt-to-Asset compare to VYCO and ADMT?
Advanced BioMedical Technologies' Debt-to-Asset of 18.50 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Devices & Instruments company?
A good Debt-to-Asset depends on the Medical Devices & Instruments industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Advanced BioMedical Technologies and its competitors. Advanced BioMedical Technologies's current Debt-to-Asset is 18.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current Debt-to-Asset of 18.50. The current Debt-to-Asset is 18.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current Debt-to-Asset is 18.50 as of Jul. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced BioMedical Technologies Business Description

Address 535 Fifth Avenue, 4th Floor, New York, NY, USA, 10017
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.